As shown for Xmab5592, a humanized IgG1 directed against HM1.24/CD317, Fc-engineered mAbs can have potent anti-myeloma activity and be synergistically active in combination with lenalidomide in vivo [27]. Here, BST2 is linked to plasma cell myeloma.